Results 91 to 100 of about 3,535 (191)

MODERN POSSIBILITIES OF MEDICAL TREATMENT OF OVERACTIVE BLADDER IN WOMEN

Медицинский совет, 2017
Overactive bladder (OAB) is a serious urination disorder which affects at least 17% of the population above 40 years old, of which 56% are women and 44% are men. M-cholinoblockers are the first line therapy and the main treatment for OAB.
I. A. Apolikhina, A. S. Chochueva, A. S. Saidova, E. A. Gorbunova   +3 more
doaj   +1 more source

Mirabegron in female patients with overactive bladder syndrome: What's new? A systematic review and meta-analysis

, 2020
Reviews assessing mirabegron's safety and efficacy, synthesize data from both genders, without providing specific details for female patients with OAB.
Salvatore, S., Grigoriadis, T., Pitsouni, E., Zacharakis, D., Athanasiou, S., Serati, M.   +5 more
core  

Mirabegron: potential off target effects and uses beyond the bladder

, 2018
The beta(3)-adrenoceptor was initially an attractive target for several pharmaceutical companies due to its high expression in rodent adipose tissue, where its activation resulted in decreased adiposity and improved metabolic outputs (such as glucose ...
da Silva Junior, Edilson Dantas, Bengtsson, Tore,, Edilson Dantas da Silva Junior, Hutchinson, Dana Sabine, Tore Bengtsson, Nodi Dehvari, Dehvari, Nodi,, Dana Sabine Hutchinson   +7 more
core   +1 more source

Sirolimus and mirabegron interaction in a hematopoietic cell transplant patient

, 2017
Purpose Hematopoietic cell transplant patients are exposed to numerous classes of medications. Transplant practitioners must vigilantly monitor for drug interactions especially involving immunosuppressants.
Jeff A Engle, Christina Fair
core   +1 more source

The efficacy and safety of mirabegron and α-adrenergic receptor antagonist in the treatment of distal ureteral stones: a systematic review and meta-analysis

Frontiers in Pharmacology
IntroductionTo systematically evaluate the efficacy and safety of mirabegron compared to α-adrenergic receptor antagonists for treating distal ureteral stones.MethodsA comprehensive search of EMBASE, PubMed, and Cochrane databases was conducted to ...
Yicheng Guo, Fengze Sun, Yini Wang, Yanfei Li, Tianqi Wang, Xiaohong Ma, Jitao Wu   +6 more
doaj   +1 more source

Efficacy of Solifenacin, Mirabegron, and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry): Protocol for a Randomized Single-Blinded Controlled Trial

JMIR Research Protocols
BackgroundAccording to International Children’s Continence Society, the first-line treatment of children with daytime urinary incontinence is standard urotherapy, eventually followed by pharmacotherapy of anticholinergics.
Ann-Kristine Mandøe Svendsen, Søren Hagstrøm, Kristina Thorsteinsson, Jason Van Batavia, Konstantinos Kamperis, Anne Estrup Olesen, Luise Borch   +6 more
doaj   +1 more source

Efficacy of Combination Therapy with Mirabegron for Anticholinergic-Resistant Neurogenic Bladder : Videourodynamic Evaluation [PDF]

, 2015
Using a videourodynamic study, we examined the efficacy of combination therapy with mirabegron for anticholinergic-resistant neurogenic bladder. We retrospectively studied 7 patients with neurogenic bladder (5 males and 2 females) who had detrusor ...
北, 雅史, 岡崎, 智, 橋爪, 和純, 松本, 成史, 小林, 進, 柿崎, 秀宏, 和田, 直樹   +6 more
core  

İdrar Kaçırma İçin Mirabegron Yüklenmiş Transdermal Bant

, 2023
Nowadays, an overactive bladder is one of the most important diseases in the world.Traditional methods used in the treatment of this disease may be insufficient. Controlled releaseof drug active ingredients is an important solution to increase the effect
Suner, Salih Can, Sancak, Eyüp Burak, Oral, Ayhan   +2 more
core  

Real-World Effects of Mirabegron in Patients with Chronic Neurogenic Detrusor Overactivity – A Retrospective Cohort Study

Research and Reports in Urology, 2020
Jörg Krebs,1 Jürgen Pannek,2,3 Franziska Rademacher,2 Jens Wöllner2 1Clinical Trial Unit, Swiss Paraplegic Centre, Nottwil, Switzerland; 2Neuro-Urology, Swiss Paraplegic Centre, Nottwil, Switzerland; 3Department of Urology, Inselspital ...
Krebs J, Pannek J, Rademacher F, Wöllner J   +3 more
doaj  

Evaluating the efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, for the treatment of overactive bladder: Systematic review and network meta-analysis

, 2017
Purpose: Overactive bladder (OAB) is a common condition affecting approximately 11% of individuals worldwide. One of the newest treatment options for OAB symptoms is mirabegron. The objective of this network meta-analysis is to evaluate the extent of the
Christel Weiss, Joy Fest, Svetlana Hetjens, Daniel Pfalzgraf   +3 more
core   +1 more source